A型肉毒毒素 (Biotecon)(Incobotulinum toxinA (Biotecon)) - 药物靶点：SNAP25_在研适应症：颈肌张力障碍，鱼尾纹，额头皱纹_专利_临床

概要

基本信息

药物类型

毒素

别名

Botulinum toxin A、Botulinum toxin A (Merz Pharma)、Incobotulinum toxin A

+ [9]

靶点

SNAP25

作用方式

抑制剂

作用机制

SNAP25 抑制剂(突触相关蛋白25 抑制剂)

治疗领域

神经系统疾病眼部疾病口颌疾病+ [3]

在研适应症

颈肌张力障碍鱼尾纹额头皱纹+ [20]

非在研适应症

阿尔茨海默症肌萎缩侧索硬化癌症疼痛+ [19]

原研机构

Biotecon Therapeutics GmbH

在研机构

Merz Pharmaceuticals GmbH

Merz Therapeutics GmbHMerz Australia Pty Ltd

+ [3]

非在研机构

权益机构

+ [1]

最高研发阶段批准上市

首次获批日期

奥地利 (2007-10-24),

流涎痉挛

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (美国)

登录后查看时间轴

结构/序列

Sequence Code 20749948

关联

119

项与 A型肉毒毒素 (Biotecon) 相关的临床试验

NCT06995287

/ Not yet recruiting临床3期IIT

Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Severe Primary Dysmenorrhea: a Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study

The objective of the study is to evaluate the global impression of improvement at 3 months following intramyometrial botulinum toxin injections via hysteroscopy in women with severe primary dysmenorrhea who have failed first-line medical treatment, compared to intramyometrial placebo injections.

开始日期2025-06-01

申办/合作机构

Nantes University Hospital

[+1]

NCT06499324

/ Recruiting临床3期IIT

Surgical Treatment of Large Incisional Hernia with Botulinum Toxin a Injection: a Double-blind Randomized Controlled Trial

After laparotomy, treating large incisional hernias (width >= 10cm) proves challenging due to the progressive retraction of lateral abdominal muscles and the separation of rectus muscles. This width is a significant risk factor for repair failure and recurrence. High rates of severe postoperative morbidity, up to 50%, are reported, linked to dissection extent, increased muscular tension, and abdominal pressure. Reconstructing normal anatomy by bringing muscles together may be impossible, leading to the use of complex procedures like component separation techniques (CST), involving large aponeurotomy for muscle relaxation. Intramuscular injection of botulinum toxin A (BTA) induces reversible flaccid paralysis, with potential benefits in hernia closure, known as "chemical CST." Retrospective studies suggest reduced muscle retraction and facilitated closure without specific morbidity. Prehabilitation with BTA aims to reduce surgical morbidity compared to repair and CST. The prospective evaluation of BTA's clinical benefits, including reduced postoperative morbidity, pain, successful abdominal closure, and decreased IH recurrence risk, is lacking. A prospective randomized double-blind placebo-controlled trial is proposed to demonstrate BTA's efficacy. The hypothesis is that BTA injection before IH repair is more effective than a placebo in reducing postoperative morbimortality. Secondary expectations include a significant reduction in complete closure of the abdominal wall without CST.

开始日期2025-01-17

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

NCT06604832

/ Recruiting临床1期IIT

Effects of PrabotulinumtoxinA-xvfs on Facial Skin Quality, Fine Wrinkles, and Texture

The goal of this split-face clinical trial is to test the efficacy of microtox in improving facial skin quality, fine wrinkles, and texture. Participants will:
* be randomly assigned to Group A (which will receive 20 units of neuromodulator on the left side of the forehead and a placebo saline treatment on the right side) or Group B (which will receive 20 units of neuromodulator on the left side of the forehead and 20 units of a different neuromodulator brand on the right side as a comparator)
* have one treatment session at week 0, and two live assessment visits at weeks 2 and 12
* have their pictures taken at each visit to track progress

开始日期2024-09-03

申办/合作机构

Evolus, Inc.

100 项与 A型肉毒毒素 (Biotecon) 相关的临床结果

登录后查看更多信息

100 项与 A型肉毒毒素 (Biotecon) 相关的转化医学

登录后查看更多信息

100 项与 A型肉毒毒素 (Biotecon) 相关的专利（医药）

登录后查看更多信息

1,143

项与 A型肉毒毒素 (Biotecon) 相关的文献（医药）

2025-12-01·Techniques in Coloproctology

Urge fecal incontinence: are intramural rectal injections of botulinum toxin a long-term treatment option?

Article

作者: Baumstarck, Karine ; Vitton, Véronique ; Onana Ndong, Philippe

BACKGROUND AND AIMS:

Unsuccessful first-line conservative treatments for managing fecal incontinence (FI) lead to considering predominantly invasive options, posing challenges in terms of cost and patient acceptance of benefit/risk ratio. Recent data from a prospective randomized study have highlighted intramural rectal botulinum toxin (BoNT/A) injection as a promising minimally invasive alternative for urge FI, demonstrating efficacy at 3 months but lacking long-term evidence. This study aimed to evaluate the sustained efficacy and injection frequency of intramural rectal BoNT/A injection in the treatment of urge FI.

METHODS:

This retrospective monocentric study enrolled all patients who underwent intramural rectal BoNT/A injection for urge FI after failed conservative therapy or sacral neuromodulation (SNM). Injections were administered during sigmoidoscopy, delivering 200 U of BoNT/A at 10 circumferentially distributed sites. Treatment effectiveness was assessed using the Cleveland clinic incontinence score (CCS) and a visual analog scale (VAS) to measure the severity of discomfort related to episodes of fecal urgency, with reinjection performed upon symptom recurrence.

RESULTS:

In total, 41 patients (34 females) were included, with a median follow-up of 24.9 (range 3.2-70.3) months. Overall, 11 patients had previously failed sacral nerve stimulation. Significant reductions were observed in the CCS (median 11 versus 7, p = 0.001) and VAS symptoms (median 4, range 0-5 versus median 2, range 0-5, p = 0.001). In total, 22 patients (53%) experienced a reduction in the CCS by over 50%. The median interval between intramural rectal BoNT/A injections was 9.8 months (range 5.3-47.9 months).

CONCLUSIONS:

This study provides the first evidence of the sustained efficacy of intramural rectal BoNT/A injection for urge FI. Further investigations are warranted to refine patient selection and reinjection criteria, evaluate socioeconomic impacts, and compare rectal BoNT/A injection with other therapeutic modalities.

2025-07-01·CLINICAL NEUROLOGY AND NEUROSURGERY

The use of onabotulinum toxin type A and other neurotoxins for the treatment of chronic migraine: An American Headache Society survey study

Article

作者: Hamilton, Kendra ; Mathew, Paul G ; Ali, Ashhar ; Agarwal, Utkarsh

PURPOSE:

OnabotA is the only US Food and Drug Administration-approved neurotoxin for chronic migraine prevention; however, non-onabotA toxins may be equally effective. Few studies have explored clinician practices and patient outcomes with non-onabotA neurotoxins. Our study aimed to generate a statistical snapshot of clinician perspectives and treatment practices regarding onabotulinum toxin A (onabotA) and other neurotoxins for chronic migraine and comorbid conditions.

METHODS:

A 15-question survey was distributed online to clinician members of the American Headache Society (AHS) assessing clinical practices using onabotA and non-onabotA toxins for chronic migraine and comorbid conditions, and descriptive analysis was performed.

RESULTS:

168 respondents (162 from the United States and 6 from Canada) completed the survey (response rate 10.1 % [168/1665]). Of 48 respondents (28 % of total) using non-onabotA toxins for chronic migraine, 27 (16 %) used incobotulinum toxin A; 23 (14 %) used abobotulinum toxin A; and 12 (7 %) used rimabotulinum toxin B. Non-onabotA toxins were predominantly used due to administration/payor imposed issues (19/48; 40 %) and cost (18/48 [38 %]). Most clinicians using non-onabotA toxins reported similar efficacy to onabotA (32/48; 67 %), while fewer reported better efficacy (9/48 [19 %]) or worse efficacy (7/48 [15 %]) than onabotA. Many respondents (114/168 [68 %]) had used neurotoxins for chronic migraine in addition to other comorbid conditions, including temporomandibular joint disorders (95/114 [83 %]) and cervical dystonia (64/114 [56 %]).

CONCLUSION:

While non-onabotA toxins are used less frequently for chronic migraine, they may have similar efficacy as onabotA and are used off-label in clinical practice due to administrative/payor issues or cost.

2025-07-01·TOXICON

Botulinum neurotoxin type DC (BoNT/DC) cleavage of VAMP3 reduces melanin production in melanocytes

Article

作者: Brideau-Andersen, Amy ; Sondergaard, Birgitte ; Le, Linh ; Boissy, Raymond E ; Malik, Shiazah

Melanin in skin and hair protects cells from UV damage; however, uneven skin color or hyperpigmentation is a common aesthetic concern. Melanin is synthesized in melanosomes, organelles within melanocytes, where tyrosinase converts tyrosine to melanin. Trafficking of tyrosinase or other cargo (eg, premelanosome protein [PMEL]) may depend on vesicle-associated membrane proteins (VAMPs); interfering with VAMPs has been reported to impact melanogenesis. Botulinum neurotoxin type DC (BoNT/DC) is a naturally occurring mosaic serotype that cleaves the SNARE proteins VAMP1-3. This study evaluated BoNT/DC as a potential treatment for hyperpigmentation by testing if it affects melanogenesis. In melanocytes, BoNT/DC cleaved VAMP2 and VAMP3, and knockdown of VAMP3, but not VAMP2, reduced melanin content, which suggests that BoNT/DC may affect melanogenesis via VAMP3 cleavage. Indeed, BoNT/DC (5 nM) produced a ∼50 % reduction in melanin content in melanocytes, and in 2 human melanocyte models, BoNT/DC, but not BoNT/A, significantly reduced melanin content (∼40-50 %) without cytotoxicity. Electron microscopy showed that BoNT/DC-treated melanocytes contained more early-stage (II) and fewer late-stage (IV) melanosomes than vehicle- or BoNT/A-treated melanocytes. Overall, BoNT/DC reduced melanin content in multiple melanocyte models, and its lightening effects are likely due to VAMP3 cleavage interfering with trafficking of cargo (eg, tyrosinase, PMEL) required for melanogenesis.

57

项与 A型肉毒毒素 (Biotecon) 相关的新闻（医药）

2025-03-21

·乐威医药

仿制药vs原研药！FDA罕见发文打破行业认知盲区

关于品牌药与仿制药之间的安全性和有效性差异是最近热点讨论话题之一，而FDA日前的一封罕见训诫信又为这一话题增加了更多的谈资，这封训诫信针对的是制药公司宣传材料中的不实结论。 FDA的处方药推广办公室（OPDP, the Office of Prescription Drug Promotion）日前向Edenbridge Pharmaceuticals发出了一封训诫信（图1），指出后者在一次会议展位上展示了一个关于其 Hemady 多发性骨髓瘤治疗的宣传面板（图2）。FDA称，该面板的内容不仅缺乏重要的风险信息，而且还宣称相对于仿制药而言，患者对Hemady的依从性更高。FDA指出，Edenbridge引用的研究并不支持这一结论，因为研究设计和方法存在问题。例如，尚不清楚服用仿制药的患者是新诊断的还是复发性多发性骨髓瘤，这两个患者群体截然不同，需要不同的治疗方案。值得注意的是，这次训诫是OPDP的首次提及此类问题。图1. FDA针对Hemady签署的训诫信部分内容。（图片来源：FDA） Hemady的活性成分是dexamethasone（地塞米松），其20 mg 片剂于2019 年 10 月 3 日获得FDA 批准，与与其他抗骨髓瘤产品联合用于治疗多发性骨髓瘤成人患者。Hemady的市场独占要到2026年底才结束，目前尚无仿制药获得FDA的批准。然而Hemady的活性成分dexamethasone作为氟化糖皮质激素药物，早在1958年就已经获批，用于风湿病、多种皮肤疾病、哮喘、结核病等多种适应症，并被WHO列入《基础药物清单》。Dexamethasone 2022年在美国被开出了超过一百万份处方，并与多种药物开出联合处方，甚至在Covid-19抗疫中也得到了广泛的推荐和使用。虽然dexamethasone最初用作抗炎类和自免疫疾病药物，但其在肿瘤学方面的应用逐渐得到开发。Hemady在2019年10月3日获得了FDA的批准，允许其20 mg dexamethasone剂型用于多发性骨髓瘤成人患者。在OPDP发出的训诫信中指出，Hemady的展位面板违反了《联邦食品、药品和化妆品法案》（FD&C法案）中关于药品标签的规定。严重性主要表现在因为宣传材料没有提供任何关于Hemady的风险信息，而Hemady是一种已知具有多重严重风险的药物，且其治疗多发性骨髓瘤的效果常常存在反复复发的症状。除此之外，Hemady的宣传材料中展示了一个表格，标题为“HEMADY®与仿制dexamethasone 4 mg片剂的患者依从性真实世界比较”，表明患者对Hemady的依从性优于仿制dexamethasone 4 mg片剂。然而FDA认为，Edenbridge引用的研究并不支持关于Hemady与仿制dexamethasone 4 mg片剂在治疗多发性骨髓瘤患者中的依从性比较的结论，因为FDA认为该研究设计和方法存在局限性。尤其是两组患者的选择方法不一致，且未控制多种变量，导致对依从性的评估可能存在偏差。此外，研究样本数量不平衡（该研究包括 3775 名服用仿制药的患者，但只有 43 名服用 Hemady 的患者），进一步削弱了研究结果的可信度。FDA因此认为，由于研究设计和方法的局限性，Edenbridge所引用的研究并未证明Hemady在患者依从性方面相对于dexamethasone 4 mg片剂的优势。总体来说，FDA认为这些宣传材料误导公众，对药物的风险和疗效做出了虚假或不完整的陈述，违反了《联邦食品、药品和化妆品法》。图2. Edenbridge的Hemady“涉事”海报内容。（图片来源：Edenbridge）这起事件的意义在于，虽然有时制药公司在宣传中可能会提到未经证实的比较（例如与仿制药的效果比较），但是FDA并未因此对品牌制药商进行过特别严厉的监管或处罚。但OPDP此番对于Edenbridge的此种训诫是之前很少发生的，FDA此前很少就品牌制剂公司发表其产品优于仿制药的结论发表看法。这封信件意图提醒制药公司注意“勿以恶小而为之”的行为，虽然有些行为尚达不到监管行动门槛的标准，但FDA已经开始关注此类动向。在更严重的情况下，FDA将发出警告信。发给Edenbridge的是FDA今年发出的第一封此类信件。过去几年中，FDA 每年只发出了几封类似信件。去年11 月，FDA曾警告 Merz Pharmaceutical 在 Instagram 上对一种用于抚平面部皱纹的注射治疗Xeomin的安全性和有效性做出误导性声明。去年9月，FDA 警告艾伯维在 Serena Williams 出演的电视广告中对偏头痛药Ubrelvy做出虚假和误导性宣传。去年8月，FDA训诫了百时美施贵宝针对肺癌药物Krazati做出虚假和误导性宣传。 FDA指出，之所以注意到 Hemady 的宣传，要归功于其“不良广告计划”（Bad Ad Program）的推出，该计划于 2010 年启动，鼓励医生和其他医疗保健专业人员报告行业广告和宣传材料中的潜在问题。据 FDA 网站称，截至 2022 年 10 月，该计划已收到 2400 多份关于潜在虚假或误导性宣传的报告。 Ref. 1.Silverman, E. FDA scolds Merz over ‘misleading’ Instagram posts featuring interior designer Nate Berkus. STAT. 14. 11. 2024. 2.Taylor, N. P. FDA slams AbbVie for misleading claims in Serena Williams ad for migraine drug Ubrelvy. Fierce Pharma. 12. 09. 2024. 3.Silverman, E. FDA scolds Bristol Myers over a misleading website for a cancer treatment. STAT. 07. 08. 2024. 4.Silverman, E. FDA scolds drugmaker over promotion that touts ‘misleading’ comparison with generics. STAT. 04. 03. 2025. 版权声明：本文内容及图片，如有侵权请联系删除。免责声明：本文内容仅作信息交流学习，并不反映任何意见及观点。往期推荐乐威医药荣获2024年度EcoVadis承诺奖牌乐威医药再获三项国家专利知识产权乐威医药公益3.12植树行动

合格传染病产品

2025-01-06

·赞Med

直面“帕”痛|帕金森病疼痛相关文献解读

点击上方“蓝字”关注我们吧！疼痛是帕金森病（PD）患者最常见的非运动症状，同时也是PD最早的症状之一，其患病率约为40-85%，尽管它严重影响着患者的生活质量，但仍经常被低估甚至漏诊，并且患者通常只能得到非系统性的治疗，据报道，大约有50%的PD疼痛患者从未接受过任何镇痛治疗。疼痛的病因和病理生理学特征复杂多样，关于治疗的建议也十分有限。目前的研究表明，除了多巴胺能系统外，5-羟色胺能、去甲肾上腺素能、谷氨酸能和GABA能途径可能也参与其中。此外，除PD本身及其他相关继发疾病（如骨关节炎）导致的疼痛外，PD的运动或非运动症状（如运动迟缓或抑郁）本身就会放大疼痛。因此，我们试图总结概述PD患者中疼痛的分类和治疗，为临床更好的疼痛管理提供建议1-2。 1.疼痛的分类 Wasner和Deuschl提出的分类方法在临床实践中使用较为广泛，他们将PD中的疼痛分为四个层次，结合了之前分类的特点和慢性疼痛分类的原则（图1）。图1：PD疼痛的分类另一种常用的分类方法是Ford的方法，它将疼痛分为五类：肌肉骨骼疼痛、肌张力障碍性疼痛、神经病理性/根性疼痛、中枢性/原发性疼痛以及静坐不能性疼痛。 2.疼痛的治疗肌肉骨骼疼痛是PD患者最常提及的类型，通常源于肌肉或关节的痉挛和疼痛，沙非胺已被证明可改善PD患者的肌肉骨骼疼痛3。此外，深部脑刺激（DBS）、非甾体抗炎药（NSAID）或其他镇痛药、关节内注射皮质类固醇或手术也可根据临床情况进行选择。肌张力障碍是一种不受控制且剧烈的肌肉收缩，导致畸形和姿势异常。肌张力障碍是多巴胺能治疗的并发症。因此推荐优化治疗以稳定多巴胺血浆水平，比如使用单胺氧化酶B（MAO-B）或儿茶酚胺-O-甲基转移酶（COMT）抑制剂，可减少白天和夜间的疼痛性运动波动以及早晨运动迟缓。在基于两项大型随机对照试验（RCT）汇总数据的事后分析中4-5，沙非胺作为左旋多巴治疗的附加疗法，与安慰剂相比，减少了疼痛药物的使用（约24%），并在PDQ-39量表的三个子项中有两项（肌肉骨骼和神经病理性疼痛）得分显著降低。神经病理性/根性疼痛可能伴有感觉异常（刺痛）和麻木，沿着外周神经或神经根的支配区域分布，一线药物包括三环类抗抑郁药（TCAs）、抗癫痫药（如普瑞巴林和加巴喷丁）以及血清素和去甲肾上腺素再摄取抑制剂（如度洛西汀）。沙非胺也可能对根性疼痛有效3。弱阿片类药物（曲马多）被视为二线药物，而利多卡因或辣椒素贴片仅推荐用于外周神经病变。中枢性疼痛是最难描述的感觉之一，热感、灼烧感、针刺感，甚至刺痛都较为常见，多巴胺能药物在缓解这种疼痛方面并不特别有效。因此，通常使用传统的镇痛药，如阿片类药物、三环类抗抑郁药（TCAs）和氯氮平。大麻素和双侧亚核团深部脑刺激（subthalamic DBS）也可能有效。静坐不能是一种以内心不安和持续的冲动去移动或改变位置为特征的疾病，在病理上与中皮质通路的多巴胺缺乏有关，氯氮平可能在治疗上有所帮助。 3.临床研究现状 2024年1月发表在《Lancet》中的《Medical, surgical, and physical treatments for Parkinson’s disease》对目前帕金森病的治疗进行了系统综述6，其中疼痛部分见表1。表1：PD非运动症状中疼痛的治疗 2021年在日本PD患者中的 2/3 期临床研究的事后分析提示4，沙非胺50mg和100mg降低了PD患者的UPDRS第17项评分，尤其是在关期。中度至重度运动迟缓和早期肌张力障碍患者可能受益于沙非胺的治疗（图2、3）。图2：在关期和开期UPDRS第17项评分从基线到第24周的平均变化*P值与安慰剂相比图3：关期（A）和开期（B）UPDRS第17项评分相对于基线的平均变化 2018年一项研究沙非胺对PD患者慢性疼痛长期（2年）疗效的研究表明5，与安慰剂相比，沙非胺显著改善了PDQ-39中第37项（“痛苦的痉挛或痉挛”，p = 0.0074）和第39项（“令人不快的热或冷”，p = 0.0209）（图4），并显著减少了26.2%伴随疼痛治疗的数量（p = 0.005），且沙非胺组中治疗 2 年后未使用止痛药的患者比例更高（p = 0.0478）（图5）。图4：PDQ-39中第37-39项从基线到第 102 周（2年）的变化图5：第102周（2年）同时使用疼痛治疗的情况 4.总结疼痛对PD患者的生活质量有重大影响，并且常常被临床医生忽视。但导致PD疼痛表现出如此广泛谱系的原因至今未明。其中，运动症状（如肌肉僵硬、姿势障碍、运动波动等）与肌肉骨骼疼痛、肌张力障碍性疼痛和神经性疼痛相关，非运动症状，如自主神经功能障碍、睡眠障碍和情绪障碍，也发挥着重要作用。因此，对疼痛进行分类有助于选择适当的管理策略。疼痛的治疗方案较为复杂，建议进行多学科综合管理，目前在中国上市的甲磺酸沙非胺片无疑为PD患者的疼痛治疗提供新选择，多篇临床研究及系统综述均阐述了其对PD患者疼痛的积极影响，且经过2年研究观察长期有效。希望在日后诊疗中，“帕”痛不再被忽视，早期识别和处理可大大减轻患者残疾，从而改善远期生活质量。参考文献 [1] Cattaneo C, Jost WH. Pain in Parkinson's Disease: Pathophysiology, Classification and Treatment. J Integr Neurosci. 2023 Sep 8;22(5):132. [2] Buhmann C, Kassubek J, Jost WH. Management of Pain in Parkinson's Disease. J Parkinsons Dis. 2020;10(s1):S37-S48. [3]Cattaneo C, Barone P, Bonizzoni E, Sardina M. Effects of Safinamide on Pain in Fluctuating Parkinson’s Disease Patients: A Post-Hoc Analysis. Journal of Parkinson’s Disease. 2017; 7: 95–101. [4] Tsuboi Y, Koebis M, Kogo Y, et al. Effects of safinamide adjunct therapy on pain in patients with Parkinson’s disease: post hoc analysis of a Japanese phase 2/3 study. J Neurol Sci 2021; 429: 118070. [5]Cattaneo C, Kulisevsky J, Tubazio V, Castellani P. Long-term efficacy of safinamide on Parkinson’s disease chronic pain. Adv Ther 2018; 35: 515–22. [6] Foltynie T, Bruno V, Fox S, Kühn AA, Lindop F, Lees AJ. Medical, surgical, and physical treatments for Parkinson's disease. Lancet. 2024 Jan 20;403(10423):305-324. [7]Bruno V, Freitas ME, Mancini D, Lui JP, Miyasaki J, Fox SH. Botulinum toxin type A for pain in advanced Parkinson’s disease. Can J Neurol Sci 2018; 45: 23–29. [8]Rieu I, Degos B, Castelnovo G, et al. Incobotulinum toxin A in Parkinson’s disease with foot dystonia: a double blind randomized trial. Parkinsonism Relat Disord 2018; 46: 9–15. [9]Iwaki H, Ando R, Tada S, et al. A double-blind, randomized controlled trial of duloxetine for pain in Parkinson’s disease. J Neurol Sci 2020; 414: 116833 提示：本材料仅供医疗卫生专业人士进行医学科学交流，不用于推广目的。

2024-12-18

·PRNewswire

Persimmon.life Introduces SmartTox® Injectable Treatment Offered at Select Massage Envy Locations

Persimmon.life will provide their medical aesthetic services at select Massage Envy Franchised locations across Arizona and California in early 2025 SCOTTSDALE, Ariz., Dec. 18, 2024 /PRNewswire/ -- Massage Envy, a national leader in skin care and the nation's No. 1 provider of massage in the U.S. collectively across its franchise network, and Persimmon.life, the leader in on-location medical aesthetic treatments, today announced a new initiative in which Persimmon will offer SmartTox® injectable treatments at select Massage Envy franchised locations across Arizona and California in early 2025. "Massage Envy is always looking for strategic relationships with brands that help address consumers' wellness goals. Persimmon's use of Massage Envy locations to provide their medical aesthetic services will not only be convenient, but will also address the needs of the modern skincare consumer," said Todd Schrader, CEO, Massage Envy Franchising. "Massage Envy has been a leader in skin care for over 16 years and looking and feeling your best is at the core of the Massage Envy brand. We are excited that our franchisees are welcoming Persimmon into their Massage Envy franchised locations." Each Persimmon service includes a personalized assessment with a Persimmon Provider, who will review goals, answer questions and explain the treatment. Sessions typically take between 15 and 20 minutes. "Massage Envy is a company that has set the standard for accessible wellness and self-care," said Mark Hadfield, CEO, Persimmon.life. "At Persimmon, we share Massage Envy's commitment to helping people look and feel their best, and we're thrilled that Persimmon will be on-site at select Massage Envy franchised locations to provide high-quality, medically-driven SmartTox® treatments." According to Persimmon.life, SmartTox®, also known as XEOMIN® and IncobotulinumtoxinA or Neurotoxin, is a double-filtered neuromodulator injection that smooths upper facial lines including frown lines, forehead lines and crow's feet without unnecessary proteins. The procedure will be available by appointment only at select Massage Envy California and Arizona franchise locations beginning in early 2025. For more information and to make an appointment, visit the Persimmon website at . About Persimmon Founded in 2021, Persimmon is at the forefront of medical aesthetics, transforming how aesthetic treatments are provided. By partnering with local businesses, Persimmon offers clients unparalleled flexibility and privacy through a growing network of highly skilled, medically-trained injection nurses available at select partnership locations. Guided by a clinical leadership team of expert nurses, Persimmon has established itself as a leader in safety, quality, and care. Their meticulously-designed training and treatment protocols ensure every client experiences top-tier results. With thousands of glowing five-star reviews, Persimmon's reputation speaks to its commitment to excellence and its ability to deliver transformative care in a setting that clients trust and enjoy. For more information, visit or follow @persimmon.life on Instagram, TikTok and Facebook. About Massage Envy Massage Envy, based in Scottsdale, Arizona, is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services and skin care offerings. Massage Envy was founded in 2002 and started offering skin care services in 2008. The brand now has over 1,000 franchise locations in 49 states that have together delivered more than 225 million massages and skin care services. For more information, visit or follow @MassageEnvy on Instagram, X and Facebook. Contact: [email protected] SOURCE Massage Envy WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与 A型肉毒毒素 (Biotecon) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	A型肉毒毒素 (Biotecon)	M03AX01	DB00083

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
颈肌张力障碍	澳大利亚	Merz Australia Pty Ltd	2023-11-28
鱼尾纹	澳大利亚	Merz Australia Pty Ltd	2023-11-28
额头皱纹	澳大利亚	Merz Australia Pty Ltd	2023-11-28
下肢痉挛	日本	Teijin Pharma Ltd.	2020-06-29
上肢痉挛	日本	Teijin Pharma Ltd.	2020-06-29
上下肢痉挛	美国	Merz Pharmaceuticals LLC	2015-12-22
眉间纹	美国	Merz Pharmaceuticals LLC	2011-07-20
眼睑痉挛	美国	Merz Pharmaceuticals LLC	2010-07-30
斜颈	美国	Merz Pharmaceuticals LLC	2010-07-30
流涎	奥地利	Merz Pharmaceuticals GmbH	2007-10-24
流涎	比利时	Merz Pharmaceuticals GmbH	2007-10-24
流涎	保加利亚	Merz Pharmaceuticals GmbH	2007-10-24
流涎	克罗地亚	Merz Pharmaceuticals GmbH	2007-10-24
流涎	塞浦路斯	Merz Pharmaceuticals GmbH	2007-10-24
流涎	捷克	Merz Pharmaceuticals GmbH	2007-10-24
流涎	丹麦	Merz Pharmaceuticals GmbH	2007-10-24
流涎	爱沙尼亚	Merz Pharmaceuticals GmbH	2007-10-24
流涎	芬兰	Merz Pharmaceuticals GmbH	2007-10-24
流涎	法国	Merz Pharmaceuticals GmbH	2007-10-24
流涎	德国	Merz Pharmaceuticals GmbH	2007-10-24

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性盆腔疼痛综合征	临床3期	法国	Merz Pharmaceuticals GmbH	2025-06-01
原发性痛经	临床3期	法国	Merz Pharmaceuticals GmbH	2025-06-01
心房颤动	临床3期	法国	Merz Pharmaceuticals GmbH	2019-09-30
智力障碍	临床3期	格鲁吉亚	Merz Pharmaceuticals GmbH	2015-02-09
智力障碍	临床3期	匈牙利	Merz Pharmaceuticals GmbH	2015-02-09
智力障碍	临床3期	波兰	Merz Pharmaceuticals GmbH	2015-02-09
智力障碍	临床3期	俄罗斯	Merz Pharmaceuticals GmbH	2015-02-09
智力障碍	临床3期	塞尔维亚	Merz Pharmaceuticals GmbH	2015-02-09
智力障碍	临床3期	乌克兰	Merz Pharmaceuticals GmbH	2015-02-09
创伤性脑损伤	临床3期	德国	Merz Pharmaceuticals GmbH	2014-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04965311 (CTgov)	临床2期	胰腺瘘 \| 胰腺癌	4	Botulinum Toxin Type A	蓋醖鹽築獵衊衊窪選鹹 = 艱鹹繭製製衊觸艱顧鏇艱構鹽遞艱鬱壓網鬱醖 (鏇築鹽衊構鹽膚襯簾構, 鏇廠獵鹽構範選鑰淵廠 ~ 簾範膚願廠築淵製網襯) 更多	-	2025-05-13
NCT04622254 (ULTRA II, CTgov)	临床3期	-	368	Placebo (Main Period: Placebo (Group P))	願窪齋艱膚窪選願繭鹹 = 廠鹽繭願齋廠憲鬱窪壓窪艱範衊觸衊遞夢醖齋 (壓構築願艱觸遞艱鹽鏇, 衊鬱鏇膚廠鹹鑰繭膚餘 ~ 廠齋願鬱淵夢餘廠顧醖) 更多	-	2024-08-06
				NT 201 (Main Period: NT 201 (Group U))	願窪齋艱膚窪選願繭鹹 = 獵蓋願壓築選觸鹹顧窪窪艱範衊觸衊遞夢醖齋 (壓構築願艱觸遞艱鹽鏇, 艱積鑰積襯觸淵壓願齋 ~ 鑰構夢壓夢艱齋遞憲觸) 更多
NCT04594213 (ULTRA I, CTgov)	临床3期	-	362	Placebo (Main Period: Placebo (Group P))	鹹鹽積醖獵膚膚糧選選 = 觸遞膚鏇齋衊鹽積糧網餘積獵艱構艱觸構構憲 (餘餘醖窪繭艱構壓製顧, 糧簾夢壓廠齋艱鹹構憲 ~ 淵憲壓網積糧鏇觸獵顧) 更多	-	2024-05-08
				NT 201 (Main Period: NT 201 (Group U))	鹹鹽積醖獵膚膚糧選選 = 壓選壓淵選艱遞築簾窪餘積獵艱構艱觸構構憲 (餘餘醖窪繭艱構壓製顧, 壓範獵積蓋淵餘鹹窪襯 ~ 鹽壓範憲衊願範範鹽夢) 更多
P8-3.004 (AAN2024)	N/A	颈肌张力障碍	451	IncobotulinumtoxinA	廠廠糧壓膚選積鑰壓築(齋壓網鏇廠構蓋憲鹽齋) = 鏇顧襯廠觸襯簾壓鏇顧觸廠艱鹹糧蓋鏇製憲蓋 (鑰衊淵構淵憲廠積醖鑰 ) 更多	积极	2024-04-09
				Placebo	廠廠糧壓膚選積鑰壓築(齋壓網鏇廠構蓋憲鹽齋) = 鹹餘襯鏇夢鹹淵範鬱淵觸廠艱鹹糧蓋鏇製憲蓋 (鑰衊淵構淵憲廠積醖鑰 ) 更多
NCT03806933 (CTgov)	临床2期	-	241	MP+NT 201 (Stage 1 and 2 Pooled: NT 201 20 U)	襯顧顧壓壓膚鏇艱網獵(鬱淵膚遞願衊夢壓夢構) = 觸膚積顧艱鏇淵繭構鑰窪鏇廠壓願廠築蓋醖壓 (壓繭積觸遞憲獵簾衊鬱, 鏇網鬱衊淵網鏇製網醖 ~ 鑰蓋獵糧鏇膚顧蓋糧壓) 更多	-	2023-10-04
				MP+NT 201 (NT 201 50 U)	襯顧顧壓壓膚鏇艱網獵(鬱淵膚遞願衊夢壓夢構) = 鏇襯膚構簾鹽鹽餘淵膚窪鏇廠壓願廠築蓋醖壓 (壓繭積觸遞憲獵簾衊鬱, 糧網構淵餘淵艱膚鑰獵 ~ 製遞鏇鬱糧觸齋糧鹽廠) 更多
MDS2023	N/A	-	451	IncobotulinumtoxinA	築網選膚繭製淵鹽艱窪(蓋糧積艱鏇鏇範遞鏇構) = 遞衊製糧選淵餘願憲齋製齋鑰衊選獵餘淵鏇夢 (鏇願鑰憲網壓窪齋鹹襯 )	-	2023-08-27
				Placebo	築網選膚繭製淵鹽艱窪(蓋糧積艱鏇鏇範遞鏇構) = 簾餘願觸衊壓壓願夢艱製齋鑰衊選獵餘淵鏇夢 (鏇願鑰憲網壓窪齋鹹襯 )
NCT02088632 (CTgov)	临床2期	三叉神经痛	6	Incobotulinumtoxina (Incobotulinumtoxina)	齋鹹顧選願鹹衊淵壓範(窪襯艱簾壓鹽選艱襯鹹) = 憲齋淵襯蓋觸蓋糧醖選鹹憲簾餘淵糧鬱醖繭鹹 (獵糧壓夢廠願鬱壓餘築, 鬱膚夢簾淵觸廠築醖壓 ~ 觸膚襯襯膚鹹遞窪淵醖) 更多	-	2023-06-28
				Placebo Comparator (Placebo Comparator)	齋鹹顧選願鹹衊淵壓範(窪襯艱簾壓鹽選艱襯鹹) = 糧醖繭製夢壓餘鬱願窪鹹憲簾餘淵糧鬱醖繭鹹 (獵糧壓夢廠願鬱壓餘築, 鏇製遞壓夢廠鏇鏇鬱鹽 ~ 繭齋網願鹽獵蓋衊選壓) 更多
P14-11.008 (AAN2023)	临床2/3期	上下肢痉挛	542	IncobotulinumtoxinA	襯構憲蓋製襯衊艱餘顧(顧衊醖鹹餘獵鹹憲鹽範) = 衊鏇製選憲壓壓獵壓廠衊鬱願齋鹽廠觸築觸鬱 (窪艱夢鬱餘觸艱齋淵夢 ) 更多	积极	2023-04-25
				Placebo	襯構憲蓋製襯衊艱餘顧(顧衊醖鹹餘獵鹹憲鹽範) = 鹹壓範願夢襯鏇積壓壓衊鬱願齋鹽廠觸築觸鬱 (窪艱夢鬱餘觸艱齋淵夢 ) 更多
P12-11.009 (AAN2023)	临床2/3期	上下肢痉挛	515	incoA injections	築製獵製夢繭窪鬱廠鏇(遞夢選壓積鹹衊網鹽獵) = 餘糧獵膚糧窪顧觸鹽襯獵齋鏇鹽鹹淵簾遞齋鹹 (鹹夢構製願醖範積鹽簾 ) 更多	-	2023-04-25
NCT04148872 (CTgov)	临床4期	面瘫 \| 联带运动	15	Neuromuscular Retraining + Chemodenervation (Neuromuscular Retraining Therapy)	壓壓壓衊顧顧齋積夢夢(襯襯夢蓋窪鹽鹽鬱鏇構) = 築醖窪憲壓廠簾壓夢憲夢襯膚糧憲膚淵鬱窪鹹 (遞淵遞夢願齋鏇築襯獵, 4.72) 更多	-	2022-09-29
				Chemodenervation (4 months) (Chemodenervation)	壓壓壓衊顧顧齋積夢夢(襯襯夢蓋窪鹽鹽鬱鏇構) = 鑰蓋顧鹽糧艱窪鬱窪鹽夢襯膚糧憲膚淵鬱窪鹹 (遞淵遞夢願齋鏇築襯獵, 3.72) 更多